文献速递主动脉疾病

急性B型主动脉夹层:一项12年单中心回顾性经验的启示

Acute Type B Aortic Dissection: Insights From a Single-Center Retrospective Experience Over 12 Years.
PubMed 文献 · J Endovasc Ther · 2024-06-19

该单中心回顾性研究纳入2008至2020年间连续130例急性B型主动脉夹层患者,比较单纯药物治疗(67例)与联合近端破口覆膜支架覆盖(63例)的结局。中位随访29.5个月,支架组动脉瘤样进展比例低于药物组(21.8% vs 42.4%),支架组假腔及胸主动脉直径减小,两组5年生存率均为76.1%。作者认为,对于初始主动脉直径≥40 mm或假腔≥22 mm的复杂程度不高的急性B型主动脉夹层患者,可考虑TEVAR。

要点

  • 支架组动脉瘤样进展21.8%,低于药物组的42.4%,主要累及胸主动脉。
  • 支架组假腔及胸主动脉直径减小,提示主动脉重塑;两组5年生存率均为76.1%。
  • 初始主动脉直径≥40 mm和假腔≥22 mm是动脉瘤样退变的独立危险因素。

核心结论

  • 本研究证实了覆膜支架覆盖近端破口治疗急性B型主动脉夹层的安全性和有效性。
  • 初始TEVAR似乎通过促进主动脉重塑减少晚期主动脉事件。
  • 考虑到TEVAR的安全性和预防晚期主动脉并发症的潜力,对于初始主动脉直径≥40 mm或假腔≥22 mm的复杂程度不高的急性B型主动脉夹层患者,可考虑TEVAR。

研究设计与样本

  • 回顾性、单中心研究,连续纳入2008至2020年间治疗的急性B型主动脉夹层患者130例。
  • 主要分析按初始治疗方式分组:单纯药物治疗复杂程度不高的急性B型主动脉夹层67例,联合支架覆盖破口63例。
  • 另对药物治疗组进行亚组分析,探讨与疾病进展相关的因素。

主要发现

  • 中位随访29.5个月,药物组动脉瘤样进展42.4%,支架组21.8%,主要累及胸主动脉。
  • 支架组显示显著的主动脉重塑,假腔和胸主动脉直径减小。
  • 初始主动脉直径≥40 mm和假腔≥22 mm是动脉瘤样退变的独立危险因素。
  • 两组5年生存率均为76.1%。

关键数值与推荐

  • 初始主动脉直径≥40 mm和假腔≥22 mm为动脉瘤样退变的独立危险因素。
  • 对于初始主动脉直径≥40 mm或假腔≥22 mm的复杂程度不高的急性B型主动脉夹层患者,可考虑TEVAR。

临床怎么用

  • 作者认为,对于初始主动脉直径≥40 mm或假腔≥22 mm的复杂程度不高的急性B型主动脉夹层患者,可考虑TEVAR。
  • 作者认为,鉴于药物治疗队列晚期主动脉事件风险较高,复杂程度不高的急性B型主动脉夹层管理中有必要纳入血管内干预,尤其是主动脉直径≥40 mm且假腔直径≥22 mm时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The treatment of acute type B aortic dissection (ATBAD) is currently a challenge for vascular surgeons, because of the early morbidity and mortality rates and the high risk of late aortic events up to 50% at 5 years. This study presents the initial outcomes of ATBAD treatment using optimal medical therapy alone or combined with proximal entry tear stent-graft coverage. Additionally, it provides an analysis of the evolution of the aortic diameter and its clinical consequences during the chronic phase in each group. MATERIALS AND METHODS: Conducted as a retrospective, single-center study, we enrolled all consecutive ATBAD patients (n=130) treated between 2008 and 2020. The primary analysis studies the entire patient cohort based on their initial management approach, namely, medical treatment alone for uncomplicated ATBAD (n=67) or combined with stent-graft entry tear coverage (n=63). We also conducted a subgroup analysis to investigate factors associated with disease progression in the medical management group. RESULTS: Median follow-up was 29.5 months. During this time aneurysmal evolution was observed in: 42.4% of cases in the medical group compared with 21.8% in the stent-graft group, primarily affecting the thoracic aorta. The stent-graft group exhibited significant aortic remodeling, with a decrease in false lumen (FL) and thoracic aortic diameters. Initial aortic diameter ≥40 mm and FL ≥22 mm were independent risk factors for aneurysmal degeneration. Five-year survival was consistent at 76.1% in both groups. CONCLUSION: This study confirms the safety and efficacy of stent-graft entry tear coverage for ATBAD. Initial thoracic endovascular aortic repair (TEVAR) appears to reduce late aortic events by promoting aortic remodeling. Considering TEVAR's safety and potential to prevent late aortic complications, it may be considered for uncomplicated ATBAD patients with an initial aortic diameter ≥40 mm or an FL ≥22 mm.Clinical ImpactThis study validates the efficacy and safety of using endovascular stent grafts to seal the proximal entry tear in cases of acute type B aortic dissections, compared to optimal medical therapy. Aortic remodelling significantly benefits from endovascular stent graft coverage of the proximal entry tear. Given the heightened risk of late aortic events observed in the medical therapy cohort, there appears to be a necessity for including endovascular interventions in the management of uncomplicated acute type B aortic dissections, particularly when aortic diameter is ≥40 mm and false lumen diameter is ≥22 mm.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Azoulay A, Serrand C, Belarbi A, et al. Acute Type B Aortic Dissection: Insights From a Single-Center Retrospective Experience Over 12 Years. J Endovasc Ther. 2024. PMID: 38898697. doi:10.1177/15266028241258401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。